Sort
10,766 grants matching “checkpoint inhibitor”
TARGETING HISTONE DEMETHYLASE KDM5B IN BREAST CANCER
$375,493Qin Yan · Yale University · R01 · FY2023 · CA
TARGETING HISTONE DEMETHYLASE KDM5B IN BREAST CANCER
$375,493Qin Yan · Yale University · R01 · FY2022 · CA
Reprogramming of the stromal microenvironment in melanoma progression and therapeutic escape
$375,431Yuhang Zhang · University Of Cincinnati · R01 · FY2021 · CA
A Novel Pathway Involving ATM, PP1 and I-2
$375,385Bo Xu · Methodist Hospital Research Institute · R01 · FY2009 · ES
Overcoming primary and secondary resistance in wild-type BRAF melanoma
$375,350Andrew E Aplin · Wistar Institute · P01 · FY2021 · CA
Inactivation of Hdac3 in the cause, prevention, and treatment of HCC
$375,240Scott Hiebert · Vanderbilt University · R01 · FY2011 · CA
HCMV regulation of monocyte/macrophage host cell signaling in viral reactivation
$375,182Andrew D Yurochko · Oregon Health & Science University · P01 · FY2024 · AI
Targeting CCR2-expressing myeloid cells to overcome immune checkpoint inhibitor resistance in glioma
$375,159Jeffrey K Harrison · University Of Florida · R01 · FY2018 · NS
Dietary trans-vaccenic acid enhances anti-tumor immunity
$375,150Jing Chen · University Of Chicago · R01 · FY2025 · CA
Dietary trans-vaccenic acid enhances anti-tumor immunity
$375,150Jing Chen · University Of Chicago · R01 · FY2023 · CA
Overcoming primary and secondary resistance in wild-type BRAF melanoma
$375,106Andrew E Aplin · Wistar Institute · P01 · FY2019 · CA
Gene expression signature based screening in Ewing sarcoma
$375,089David J Gordon · University Of Iowa · R37 · FY2021 · CA
Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC
$375,001Cathy A Swindlehurst · Novomedix, Inc. · R43 · FY2019 · HL
Prospective validation of a radiomics-based multi-modal predictive model for metastatic non-small cell lung cancer patients treated with PD-1 immunotherapy
$375,000Petr Jordan · Onc.Ai, Inc. · R44 · FY2025 · CA
TRANSPOSASE PROTEIN METNASE IN LEUKEMIC DECATENATION
$375,000Robert A Hromas · University Of New Mexico · R01 · FY2010 · HL
TRANSPOSASE PROTEIN METNASE IN LEUKEMIC DECATENATION
$375,000Robert A Hromas · University Of New Mexico · R01 · FY2009 · HL
TRANSPOSASE PROTEIN METNASE IN LEUKEMIC DECATENATION
$375,000Robert A Hromas · University Of New Mexico · R01 · FY2008 · HL
TRANSPOSASE PROTEIN METNASE IN LEUKEMIC DECATENATION
$375,000Robert A Hromas · University Of Florida · R01 · FY2011 · HL
Augmenting Quadruple Negative Breast Cancer Treatment by ADRM1 Inhibitor Up284
$374,850Balasubramanyam Karanam · Tuskegee University · U54 · FY2023 · MD
Sensitizing high grade serous cancers to immunotherapy through the induction of DNA damage
$374,836Karen McLean · Roswell Park Cancer Institute Corp · R01 · FY2024 · CA
Novel therapeutics for targeting checkpoint dysfunction in cancer
$374,819Weei-Chin Lin · Baylor College Of Medicine · R01 · FY2023 · CA
In Situ characterization and manipulation of tumor immune cell metabolomics using implantable microdevices
$374,782Oliver Jonas · Brigham And Women'S Hospital · R01 · FY2019 · CA
Project 3: Modulation of the head and neck tumor immune microenvironment by targeting the TAM family of receptors
$374,756Deric L Wheeler · University Of Wisconsin-Madison · P50 · FY2022 · CA
Inactivation of Hdac3 in the cause, prevention, and treatment of HCC
$374,701Scott Hiebert · Vanderbilt University · R01 · FY2012 · CA
Collaborative Project
$374,678Jeremy M. Boss · Emory University · U19 · FY2021 · AI